The U.S.Food and Drug Administration has approved a DNA test to ascertain how transplant patients respond to treatment for cytomegalovirus or CMV, according to an FDA statement, to improve post-surgery recovery. The COBAS AmpliPrep / COBAS TaqMan CMV Test, developed by Swiss pharmaceutical firm Roche’s molecular diagnostics division in Somerville, New Jersey, determines the amount of [...]